Cognitive Impairment in Parkinson’s Disease: What We Know so Far

References

• Aarsland D, Larsen JP, Karlsen K, Lim NG, Tandberg E. Mental symptoms in Parkinson’s disease are important contributors to caregiver distress. Int J Geriat Psychiatry. 1999;14:866–874. doi:10.1002/(SICI)1099-1166(199910)14:10Ã866::AID-GPS38>3.0.CO;2-Z
   PubMed Web of Science ®Google Scholar
• Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson’s disease: a population-based, prospective study. J Am Geritatr Soc. 2000;48(8):938–942. doi:10.1111/j.1532-5415.2000.tb06891.x
   PubMed Web of Science ®Google Scholar
• Levy G, Tang MX, Louis ED, et al. The association of incident dementia with mortality in PD. Neurology. 2002;59:1708–1713. doi:10.1212/01.WNL.0000036610.36834.E0
   PubMed Web of Science ®Google Scholar
• Santangelo G, Vitale C, Picillo M, et al. Mild cognitive impairment in newly diagnosed Parkinson’s disease: a longitudinal prospective study. Parkinsonism Relat Disord. 2015;21(10):1219–1226. doi:10.1016/j.parkreldis.2015.08.024
   PubMed Web of Science ®Google Scholar
• Hely A, Morris JG, Reid WG, Traffificante R. Sydney multicenter study of Parkinson’s disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord. 2005;20(2):190–199. doi:10.1002/mds.20324
   PubMed Web of Science ®Google Scholar
• Williams-Gray CH, Mason SL, Evans JR, et al. The CamPaIGN study of Parkinson’s disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry. 2013;84(11):1258–1264. doi:10.1136/jnnp-2013-305277
   PubMed Web of Science ®Google Scholar
• Aarsland D, Creese B, Politis M, et al. Cognitive decline in Parkinson disease. Nat Rev Neurol. 2017;13(4):217–231. doi:10.1038/nrneurol.2017.27
   PubMed Web of Science ®Google Scholar
• Dalrymple-Alford JC, Livingston L, MacAskill MR, et al. Characterizing mild cognitive impairment in Parkinson’s disease. Mov Disord. 2011;26(4):629–636. doi:10.1002/mds.23592
   PubMed Web of Science ®Google Scholar
• Litvan I, Goldman JG, Tröster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: movement disorder society task force guidelines. Mov Disord. 2012;27:349–356. doi:10.1002/mds.24893
   PubMed Web of Science ®Google Scholar
• Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord. 2007;22(12):1689–1707. doi:10.1002/mds.21507
   PubMed Web of Science ®Google Scholar
• Litvan I, Aarsland D, Adler CH, et al. MDS task force on mild cognitive impairment in Parkinson’s disease: critical review of PD-MCI. Mov Disord. 2011;26(10):1814–1824. doi:10.1002/mds.23823
   PubMed Web of Science ®Google Scholar
• Marras C, Armstrong MJ, Meaney CA, et al. Measuring mild cognitive impairment in patients with Parkinson’s disease. Mov Disord. 2013;28:626–633. doi:10.1002/mds.25426
   PubMed Web of Science ®Google Scholar
• Lawrence BJ, Gasson N, Loftus AM. Prevalence and subtypes of mild cognitive impairment in Parkinson’s disease. Sci Rep. 2016;6:33929. doi:10.1038/srep33929
   PubMed Web of Science ®Google Scholar
• Aarsland D, Bronnick K, Williams-Gray C, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology. 2010;75(12):1062–1069. doi:10.1212/WNL.0b013e3181f39d0e
   PubMed Web of Science ®Google Scholar
• Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord. 2005;20(10):1255–1263. doi:10.1002/mds.20527
   PubMed Web of Science ®Google Scholar
• Williams-Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson’s disease: 5 year follow-up of the CamPaIGN cohort. Brain. 2009;132(11):2958–2969. doi:10.1093/brain/awp245
   PubMed Web of Science ®Google Scholar
• Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23(6):837–844. doi:10.1002/mds.21956
   PubMed Web of Science ®Google Scholar
• Jozwiak N, Postuma RB, Montplaisir J, et al. REM sleep behavior disorder and cognitive impairment in Parkinson’s disease. Sleep. 2017;40:8. doi:10.1093/sleep/zsx101
   Web of Science ®Google Scholar
• Vendette M, Gagnon JF, Décary A, et al. REM sleep behavior disorder predicts cognitive impairment in Parkinson disease without dementia. Neurology. 2007;69(19):1843–1849. doi:10.1212/01.wnl.0000278114.14096.74
   Web of Science ®Google Scholar
• Goldman JG, Ghode RA, Ouyang B, Bernard B, Goetz CG, Stebbins GT. Dissociations among daytime sleepiness, night time sleep, and cognitive status in Parkinson’s disease. Parkinsonism Relat Disord. 2013;19:806–811. doi:10.1016/j.parkreldis.2013.05.006
   PubMed Web of Science ®Google Scholar
• Goldman JG, Stebbins GT, Leung V, Tilley BC, Goetz CG. Relationships among cognitive impairment, sleep, and fatigue in Parkinson’s disease using the MDS-UPDRS. Parkinsonism Relat Disord. 2014;20(11):1135–1139. doi:10.1016/j.parkreldis.2014.08.001
   PubMed Web of Science ®Google Scholar
• Mata IF, Leverenz JB, Weintraub D, et al. APOE, MAPT, and SNCA genes and cognitive performance in parkinson disease. JAMA Neurol. 2014;71(11):1405–1412. doi:10.1001/jamaneurol.2014.1455
   PubMed Web of Science ®Google Scholar
• Morley JF, Xie SX, Hurtig HI, et al. Genetic influences on cognitive decline in Parkinson’s disease. Mov Disord. 2012;27:512–518. doi:10.1002/mds.24946
   PubMed Web of Science ®Google Scholar
• Piredda R, Desmarais P, Masellis M, Gasca-Salas C. Cognitive and psychiatric symptoms in genetically determined Parkinson’s disease: a systematic review. Eur J Neurol. 2020;27(2):229–234. doi:10.1111/ene.14115
   Web of Science ®Google Scholar
• Smith C, Malek N, Grosset K, Cullen B, Gentleman S, Grosset DG. Neuropathology of dementia in patients with Parkinson’s disease: a systematic review of autopsy studies. J Neurol Neurosurg Psychiatry. 2019;90(11):1234–1243. doi:10.1136/jnnp-2019-321111
   PubMed Web of Science ®Google Scholar
• Masliah E, Rockenstein E, Veinbergs I, et al. Beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer’s disease and Parkinson’s disease. Proc Natl Acad Sci U S A. 2001;98(21):12245–12250. doi:10.1073/pnas.211412398
   Web of Science ®Google Scholar
• Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM. Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci. 2010;30(21):7281–7289. doi:10.1523/JNEUROSCI.0490-10.2010
   PubMed Web of Science ®Google Scholar
• Horvath J, Herrmann FR, Burkhard PR, Bouras C, Kövari E. Neuropathology of dementia in a large cohort of patients with Parkinson’s disease. Parkinsonism Relat Disord. 2013;19(10):864. doi:10.1016/j.parkreldis.2013.05.010
   PubMed Web of Science ®Google Scholar
• Ruffmann C, Calboli FC, Bravi I, et al. Cortical Lewy bodies and Aβ burden are associated with prevalence and timing of dementia in Lewy body diseases. Neuropathol Appl Neurobiol. 2016;42(5):436–450. doi:10.1111/nan.12294
   Web of Science ®Google Scholar
• Sabbagh MN, Adler CH, Lahti TJ, et al. Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis Assoc Disord. 2009;23(3):295–297. doi:10.1097/WAD.0b013e31819c5ef4
   PubMed Web of Science ®Google Scholar
• Kotzbauer PT, Cairns NJ, Campbell MC, et al. Pathologic accumulation of α-synuclein and Aβ in Parkinson disease patients with dementia. Arch Neurol. 2012;69(10):1326–1331. doi:10.1001/archneurol.2012.1608
   Google Scholar
• Compta Y, Parkkinen L, O’Sullivan SS, et al. Lewy- and Alzheimer type pathologies in Parkinson’s disease dementia: which is more important? Brain. 2011;134(5):1493–1505. doi:10.1093/brain/awr031
   PubMedGoogle Scholar
• Perry EK, Curtis M, Dick DJ. Cholinergic correlates of cognitive impairment in Parkinson’s disease: comparisons with Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 1985;48:413–421. doi:10.1136/jnnp.48.5.413
   PubMed Web of Science ®Google Scholar
• Whitehouse PJ, Hedreen JC, White CL, Price DL. Basal forebrain neurons in the dementia of Parkinson’s disease. Ann Neurol. 1983;13:243–248. doi:10.1002/ana.410130304
   PubMed Web of Science ®Google Scholar
• Perry RH, Tomlinson BE, Candy JM, et al. Cortical cholinergic deficit in mentally impaired Parkinsonian patients. Lancet. 1983;2:789–790. doi:10.1016/S0140-6736(83)92317-6
   PubMed Web of Science ®Google Scholar
• Mattila PM, Roytta M, Lonnberg P, Marjamäki P, Helenius H, Rinne JO. Choline acetyltransferase activity and striatal dopamine receptors in Parkinson’s disease in relation to cognitive impairment. Acta Neuropathol. 2001;102:160–166. doi:10.1007/s004010100372
   PubMed Web of Science ®Google Scholar
• Pillon J, Kahan J, Zrinzo L, et al. The nucleus basalis of Meynert: a new target for deep brain stimulation in dementia? Neurosci Biobehav Rev. 2013;37(10):2676–2688. doi:10.1016/j.neubiorev.2013.09.003
   Web of Science ®Google Scholar
• Silbert LC, Kaye J. Neuroimaging and cognition in Parkinson’s disease dementia. Brain Pathol. 2010;20(3):646–653. doi:10.1111/j.1750-3639.2009.00368.x
   PubMed Web of Science ®Google Scholar
• Kuhl DE, Minoshima S, Fessleretal JA. Invivo mapping of cholinergic terminals in normal aging, Alzheimer’s disease, and Parkinson’s disease. Ann Neurol. 1996;40(3):399–410. doi:10.1002/ana.410400309
   PubMed Web of Science ®Google Scholar
• Christopher L. Combined insular and striatal dopamine dysfunction are associated with executive deficits in Parkinson’s disease with mild cognitive impairment. Brain. 2014;137(2):565–575. doi:10.1093/brain/awt337
   Google Scholar
• Siepel FJ, Brønnick KS, Booijetal J. Cognitive executive impairment and dopaminergic deficits in de novo Parkinson’s disease. Mov Disord. 2014;29(14):1802–1808. doi:10.1002/mds.26051
   PubMed Web of Science ®Google Scholar
• Christopher L, Duff-Canning S, Koshimori Y, et al. Salience network and parahippocampal dopamine dysfunction in memory-impaired Parkinson disease. Ann Neurol. 2015;77(2):269–280. doi:10.1002/ana.24323
   Web of Science ®Google Scholar
• Compta Y, Buongiorno M, Bargalló N, et al. White matter hyperintensities, cerebrospinal amyloid-β and dementia in Parkinson’s disease. J Neurol Sci. 2016;367:284–290. doi:10.1016/j.jns.2016.06.009
   Web of Science ®Google Scholar
• González-Redondo R, Toledo J, Clavero P, et al. The impact of silent vascular brain burden in cognitive impairment in Parkinson’ disease. Eur J Neurol. 2012;19(8):1100–1107. doi:10.1111/j.1468-1331.2012.03682.x
   PubMed Web of Science ®Google Scholar
• Sunwoo MK, Jeon S, Ham JH, et al. The burden of white matter hyperintensities is a predictor of progressive mild cognitive impairment in patients with Parkinson’s disease. Eur J Neurol. 2014;21(6):922–e50. doi:10.1111/ene.12412
   PubMed Web of Science ®Google Scholar
• Chahine LM, Dos SC, Fullard M, et al. Modifiable vascular risk factors, white matter disease, and cognition in early Parkinson’s disease. Eur J Neurol. 2019;26(2):246–e18. doi:10.1111/ene.13797
   PubMed Web of Science ®Google Scholar
• Dalaker TO, Larsen JP, Dwyer MG, et al. White matter hyperintensities do not impact cognitive function in patients with newly diagnosed Parkinson’s disease. Neuroimage. 2009;47(4):2083–2089. doi:10.1016/j.neuroimage.2009.06.020
   PubMed Web of Science ®Google Scholar
• Schwartz RS, Halliday GM, Soh D, Cordato DJ, Kril JJ. Impact of small vessel disease on severity of motor and cognitive impairment in Parkinson’s disease. J Clin Neurosci. 2018;58:70–74. doi:10.1016/j.jocn.2018.10.029
   PubMed Web of Science ®Google Scholar
• Compta Y, Martí MJ, Ibarretxe-Bilbao N, et al. Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson’s disease. Mov Disord. 2009;24(15):2203–2210. doi:10.1002/mds.22594
   PubMed Web of Science ®Google Scholar
• Gmitterová K, Gawinecka J, Llorens F, Varges D, Valkovi˘c P, ZI. Cerebrospinal fluid markers analysis in the differential diagnosis of dementia with Lewy bodies and Parkinson’s disease dementia. Eur Arch Psychiatry Clin Neurosci. 2020;270(4):461–470. doi:10.1007/s00406-018-0928-9
   Web of Science ®Google Scholar
• Maetzler W, Liepelt I, Reimold M, et al. Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis. 2009;34:107–112. doi:10.1016/j.nbd.2008.12.008
   Web of Science ®Google Scholar
• Modreanu R, Cerquera SC, Martí MJ, et al. Cross-sectional and longitudinal associations of motor fluctuations and non-motor predominance with cerebrospinal τ and Aβ as well as dementia-risk in Parkinson’s disease. J Neurol Sci. 2017;373:223–229. doi:10.1016/j.jns.2016.12.064
   Web of Science ®Google Scholar
• Hall S, Öhrfelt A, Constantinescu R, et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol. 2012;69(11):1445–1452. doi:10.1001/archneurol.2012.1654
   PubMedGoogle Scholar
• Vranová HP, Hényková E, Kaiserová M, et al. Tau protein, beta-amyloid 1−42 and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia. J Neurol Sci. 2014;343:120–124. doi:10.1016/j.jns.2014.05.052
   Web of Science ®Google Scholar
• Parnetti L, Tiraboschi P, Lanari A, et al. Cerebrospinal fluid biomarkers in Parkinson’s disease with dementia and dementia with Lewy bodies. Biol Psychiatry. 2008;64:850–855. doi:10.1016/j.biopsych.2008.02.016
   PubMed Web of Science ®Google Scholar
• Johar I, Mollenhauer B, Aarsland D. Cerebrospinal fluid biomarkers of cognitive decline in Parkinson’s disease. Int Rev Neurobiol. 2017;132:275–294.
   Web of Science ®Google Scholar
• Siderowf A, Xie SX, Hurtig H, et al. CSF amyloid 1-42 predicts cognitive decline in Parkinson disease. Neurology. 2010;75(12):1055–1061. doi:10.1212/WNL.0b013e3181f39a78
   Web of Science ®Google Scholar
• Terrelonge M, Marder KS, Weintraub D, Alcalay RN. CSF β-amyloid 1-42 predicts progression to cognitive impairment in newly diagnosed Parkinson disease. J Mol Neurosci. 2016;58(1):88–92. doi:10.1007/s12031-015-0647-x
   PubMed Web of Science ®Google Scholar
• Schrag A, Siddiqui UF, Anastasiou Z, Weintraub D, Schott JM. Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson’s disease: a cohort study. Lancet Neurol. 2016;16(1):66–75. doi:10.1016/S1474-4422(16)30328-3
   Web of Science ®Google Scholar
• Compta Y, Pereira JB, Ríos J, et al. Combined dementia-risk biomarkers in Parkinson’s disease: a prospective longitudinal study. Parkinsonism Relat Disord. 2013;19(8):717–724. doi:10.1016/j.parkreldis.2013.03.009
   PubMed Web of Science ®Google Scholar
• Bäckström DC, Eriksson Domellöf M, Linder J, et al. Cerebrospinal fluid patterns and the risk of future dementia in early, incident Parkinson disease. JAMA Neurol. 2015;72:1175–1182. doi:10.1001/jamaneurol.2015.1449
   PubMed Web of Science ®Google Scholar
• Fereshtehnejad SM, Zeighami Y, Dagher A, Postuma RB. Clinical criteria for subtyping Parkinson’s disease: biomarkers and longitudinal progression. Brain. 2017;140(7):1959–1976. doi:10.1093/brain/awx118
   PubMedGoogle Scholar
• Eusebi P, Giannandrea D, Biscetti L, et al. Diagnostic utility of cerebrospinal fluid α-synuclein in Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2017;32(10):1389–1400. doi:10.1002/mds.27110
   PubMed Web of Science ®Google Scholar
• Hall S, Surova Y, Ohrfelt A, et al. CSF biomarkers and clinical progression of Parkinson disease. Neurology. 2015;84:57–63. doi:10.1212/WNL.0000000000001098
   PubMed Web of Science ®Google Scholar
• Stewart T, Liu C, Ginghina C, et al. Cerebrospinal fluid α-Synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. Am J Pathol. 2014;184:966–975. doi:10.1016/j.ajpath.2013.12.007
   PubMed Web of Science ®Google Scholar
• Pagano G, De Micco R, Yousaf T, Wilson H, Chandra A, Politis M. REM behavior disorder predicts motor progression and cognitive decline in Parkinson disease. Neurology. 2018;91(10):894–906. doi:10.1212/WNL.0000000000006134
   Web of Science ®Google Scholar
• Hansson O, Hall S, Ohrfelt A, et al. Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease. Alzheimers Res Ther. 2014;6:25. doi:10.1186/alzrt255
   PubMed Web of Science ®Google Scholar
• Compta Y, Valente T, Saura J, et al. Correlates of cerebrospinal fluid levels of oligomeric- and total-α-synuclein in premotor, motor and dementia stages of Parkinson’s disease. J Neurol. 2015;262(2):294–306. doi:10.1007/s00415-014-7560-z
   PubMed Web of Science ®Google Scholar
• Cammisuli DM, Crowe S. Spatial disorientation andexecutive dysfunction in elderly nondemented patients with Parkinson’s disease. Neuropsychiatr Dis Treat. 2018;14:2531–2539. doi:10.2147/NDT.S173820
   Web of Science ®Google Scholar
• Kalbe E, Rehberg SP, Heber I, et al. Subtypes of mild cognitive impairment in patients with Parkinson’s disease: evidence from the LANDSCAPE study. J Neurol Neurosurg Psychiatry. 2016;87:1099–1105. doi:10.1136/jnnp-2016-313838
   PubMed Web of Science ®Google Scholar
• Peran P, Rascol O, Demonet JF, et al. Deficit of verb generation in nondemented patients with Parkinson’s disease. Mov Disord. 2003;18:150–156. doi:10.1002/mds.10306
   PubMed Web of Science ®Google Scholar
• Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA. Evolution of cognitive dysfunction in an incident Parkinson’s disease cohort. Brain. 2007;130(7):1787–1798. doi:10.1093/brain/awm111
   PubMed Web of Science ®Google Scholar
• Kehagia AA, Barker RA, Robbins TW. Cognitive impairment in Parkinson’s disease: the dual syndrome hypothesis. Neurodegener Dis. 2013;11(2):79–92. doi:10.1159/000341998
   PubMed Web of Science ®Google Scholar
• Wood KL, Myall DJ, Livingston L, et al. Different PD-MCI criteria and risk of dementia. NPJ Parkinsons Dis. 2016;2(1):15027. doi:10.1038/npjparkd.2015.27
   Google Scholar
• Domellof ME, Ekman U, Forsgren L, Elgh E. Cognitive function in the early phase of Parkinson’s disease, a five-year follow-up. Acta Neurol Scand. 2015;132:79–88. doi:10.1111/ane.12375
   PubMed Web of Science ®Google Scholar
• Pedersen KF, Larsen JP, Tysnes OB, Alves G. Natural course of mild cognitive impairment in Parkinson disease: a 5-year population-based study. Neurology. 2017;88(8):767–774. doi:10.1212/WNL.0000000000003634
   PubMed Web of Science ®Google Scholar
• Saredakis D, Collins-Praino LE, Gutteridge DS, Stephan BCM, Keage HAD. Conversion to MCI and dementia in Parkinson’s disease: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2019;65:20–31. doi:10.1016/j.parkreldis.2019.04.020
   PubMed Web of Science ®Google Scholar
• Kempster PA, O’Sullivan SS, Holton JL, Revesz T, Lees AJ. Relationships between age and late progression of Parkinson’s disease: a clinico-pathological study. Brain. 2010;133(6):1755–1762. doi:10.1093/brain/awq059
   PubMedGoogle Scholar
• Bronnick K, Ehrt U, Emre M, et al. Attentional deficits affect activities of daily living in dementia-associated with Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2006;77(10):1136–1142. doi:10.1136/jnnp.2006.093146
   Web of Science ®Google Scholar
• Weintraub D, Moberg PJ, Culbertson WC, Duda JE, Stern MB. Evidence for impaired encoding and retrieval memory profiles in Parkinson disease. Cogn Behav Neurol. 2004;17(4):195–200.
   PubMedGoogle Scholar
• Cumming JL, Huber SJ. Visuospatial abnormalities in Parkinson’s disease. In: Huber SJ, Cummings JL, editors. Parkinson’s Disease. Neurobehavioral Aspects. New York: Oxford University Press; 1992:59–73.
   Google Scholar
• Aarsland D, Brønnick K, Ehrt U, et al. Neuropsychiatric symptoms in patients with Parkinson’s disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry. 2007;78(1):36–42. doi:10.1136/jnnp.2005.083113
   PubMed Web of Science ®Google Scholar
• McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65:1863–1872. doi:10.1212/01.wnl.0000187889.17253.b1
   PubMed Web of Science ®Google Scholar
• Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591–1601. doi:10.1002/mds.26424
   PubMed Web of Science ®Google Scholar
• Skorvanek M, Goldman JG, Jahanshahi M, et al. Global scales for cognitive screening in Parkinson’s disease: critique and recommendations. Mov Disord. 2018;33(2):208–218. doi:10.1002/mds.27233
   PubMed Web of Science ®Google Scholar
• Nasreddine Z, Phillips N, BÃcdirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–699. doi:10.1111/j.1532-5415.2005.53221.x
   PubMed Web of Science ®Google Scholar
• Dalrymple-Alford JC, MacAskill MR, Nakas CT, et al. The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology. 2010;75(19):1717–1725. doi:10.1212/WNL.0b013e3181fc29c9
   PubMed Web of Science ®Google Scholar
• Jurica PJ, Leitten CL, Mattis S. Psychological assessment resources, 2001. Dementia Rating Scale-2 (DRS-2). Arch Clin Neuropsychol. 2004;19:145–147. doi:10.1016/j.acn.2003.07.003
   Google Scholar
• Matteau E, Dupre N, Langlois M, Provencher P, Simard M. Clinical validity of the Mattis Dementia Rating Scale-2 in Parkinson disease with MCI and dementia. J Geriatr Psychiatry Neurol. 2012;25:100e6.
   Web of Science ®Google Scholar
• Bezdicek O, Michalec J, Nikolai T, et al. Clinical validity of the Mattis Dementia Rating Scale in differentiating mild cognitive impairment in Parkinson’s disease and normative data. Dement Geriatr Cogn Disord. 2015;39(5–6):303–311. doi:10.1159/000375365
   PubMed Web of Science ®Google Scholar
• Pagonabarraga J, Kulisevsky J, Llebaria G, García-Sanchez C, Pascual-Sedano B, Gironell A. Parkinson’s disease-cognitive rating scale: a new cognitive scale specifific for Parkinson’s disease. Mov Disord. 2008;23:998–1005. doi:10.1002/mds.22007
   PubMed Web of Science ®Google Scholar
• Nie K, Zhang Y, Wang L, et al. A pilot study of psychometric properties of the Beijing version of Montreal Cognitive Assessment in patients with idiopathic Parkinson’s disease in China. J Clin Neurosci. 2012;19:1497–1500. doi:10.1016/j.jocn.2011.11.039
   PubMed Web of Science ®Google Scholar
• Beyer MK, Larsen JP, Aarsland D. Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies. Neurology. 2007;69(8):747–754. doi:10.1212/01.wnl.0000269666.62598.1c
   Web of Science ®Google Scholar
• Sanchez-Castaneda C, Rene R, Ramirez-Ruiz B, et al. Correlations between gray matter reductions and cognitive deficits in dementia with Lewy bodies and Parkinson’s disease with dementia. Mov Disord. 2009;24(12):1740–1746. doi:10.1002/mds.22488
   Web of Science ®Google Scholar
• Junqué C, Ramírez-Ruiz B, Tolosa E, et al. Amygdalar and hippocampal MRI volumetric reductions in Parkinson’s disease with dementia. Mov Disord. 2005;20(5):540–544. doi:10.1002/mds.20371
   Web of Science ®Google Scholar
• Pagonabarraga J, Corcuera-Solano I, Vives-Gilabert Y, et al. Pattern of regional cortical thinning associated with cognitive deterioration in Parkinson’s disease. PLoS One. 2013;8(1):e54980. doi:10.1371/journal.pone.0054980
   PubMed Web of Science ®Google Scholar
• Burton EJ, McKeith IG, Burn DJ, Williams ED, O’Brien JT. Cerebral atrophy in Parkinson’s disease with and without dementia: a comparison with Alzheimer’s disease, dementia with Lewy bodies and controls. Brain. 2004;127(Pt 4):791–800. doi:10.1093/brain/awh088
   Google Scholar
• Rektorova I, Biundo R, Marecek R, Weis L, Aarsland D, Antonini A. Grey matter changes in cognitively impaired Parkinson’s disease patients. PLoS One. 2014;9(01):e85595. doi:10.1371/journal.pone.0085595
   Google Scholar
• Segura B, Baggio HC, Marti MJ, et al. Cortical thinning associated with mild cognitive impairment in Parkinson’s disease. Mov Disord. 2014;29(12):1495–1503. doi:10.1002/mds.25982
   Web of Science ®Google Scholar
• Gasca-Salas C, García-Lorenzo D, Garcia-Garcia D, et al. Parkinson’s disease with mild cognitive impairment: severe cortical thinning antedates dementia. Brain Imaging Behav. 2019;13:180–188. doi:10.1007/s11682-017-9751-6
   Web of Science ®Google Scholar
• Zarei M, Ibarretxe-Bilbao N, Compta Y, et al. Cortical thinning is associated with disease stages and dementia in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2013;84(8):875–881. doi:10.1136/jnnp-2012-304126
   PubMed Web of Science ®Google Scholar
• Mak E, Su L, Williams GB, et al. Baseline and longitudinal grey matter changes in newly diagnosed Parkinson’s disease: ICICLE-PD study. Brain. 2015;138(10):2974–2986. doi:10.1093/brain/awv211
   Google Scholar
• Olde Dubbelink KT, Schoonheim MM, Deijen JB, Twisk JW, Barkhof F, Berendse HW. Functional connectivity and cognitive decline over 3 years in Parkinson disease. Neurology. 2014;83(22):2046–2053. doi:10.1212/WNL.0000000000001020
   PubMed Web of Science ®Google Scholar
• Wolters AF, SCF VDW, Leentjens AFG, Duits AA, Jacobs HIL, Kuijf ML. Resting-state fMRI in Parkinson’s disease patients with cognitive impairment: a meta-analysis. Parkinsonism Relat Disord. 2019;62:16–27. doi:10.1016/j.parkreldis.2018.12.016
   PubMed Web of Science ®Google Scholar
• Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease. Cochrane Database Syst Rev. 2012;(3):CD006504.
   Web of Science ®Google Scholar
• Wang HF, Yu JT, Tang SW, et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry. 2015;86:135–143. doi:10.1136/jnnp-2014-307659
   PubMed Web of Science ®Google Scholar
• Meng YH, Wang PP, Song YX, Wang JH. Cholinesterase inhibitors and memantine for Parkinson’s disease dementia and Lewy body dementia: a meta-analysis. Exp Ther Med. 2019;17(3):1611–1624. doi:10.3892/etm.2018.7129
   PubMed Web of Science ®Google Scholar
• Dubois B, Tolosa E, Katzenschlager R, et al. Donepezil in Parkinson’s disease dementia: a randomized, double-blind efficacy and safety study. Mov Disord. 2012;27(10):1230–1238. doi:10.1002/mds.25098
   PubMed Web of Science ®Google Scholar
• Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in parkinson’s disease: a randomised controlled study. J Neurol Neurosurg Psychiatry. 2002;72(6):708–712.
   PubMed Web of Science ®Google Scholar
• Mamikonyan E, Xie SX, Melvin E, Weintraub D. Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study. Mov Disord. 2015;30(7):912–918. doi:10.1002/mds.26236
   PubMed Web of Science ®Google Scholar
• Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med. 2004;351(24):2509–2518. doi:10.1056/NEJMoa041470
   PubMed Web of Science ®Google Scholar
• Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson’s disease-an evidence-based medicine review. Mov Disord. 2019;34(2):180–198. doi:10.1002/mds.27602
   PubMed Web of Science ®Google Scholar
• Leroi I, Overshott R, Byrne EJ, Daniel E, Burns A. Randomized controlled trial of memantine in dementia associated with Parkinson’s disease. Mov Disord. 2009;24(8):1217–1221. doi:10.1002/mds.22495
   PubMed Web of Science ®Google Scholar
• Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009;8(7):613–618. doi:10.1016/S1474-4422(09)70146-2
   PubMed Web of Science ®Google Scholar
• Caballol N, Martí MJ, Tolosa E. Cognitive dysfunction and dementia in Parkinson disease. Mov Disord. 2007;22(17):S358–366. doi:10.1002/mds.21677
   Google Scholar
• Factor S, Friedman J, Lannon M, Oakes D, Bourgeois K, Group PS. Clozapine for the treatment of drug-induced psychosis in Parkinson’s disease: results of the 12 week open label extension in the PSYCLOPS trial. Mov Disord. 2001;16:135–139. doi:10.1002/1531-8257(200101)16:1<135::AID-MDS1006>3.0.CO;2-Q
   PubMed Web of Science ®Google Scholar
• Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry. 2004;75(5):689–695. doi:10.1136/jnnp.2003.029868
   PubMed Web of Science ®Google Scholar
• Morgante L, Epifanio A, Spina E, et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol. 2004;27:153–156. doi:10.1097/01.wnf.0000136891.17006.ec
   PubMed Web of Science ®Google Scholar
• Merims D, Balas M, Peretz C, Shabtai H, Giladi N. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson’s disease psychosis. Clin Neuropharmacol. 2006;29(6):331–337. doi:10.1097/01.WNF.0000236769.31279.19
   PubMed Web of Science ®Google Scholar
• Ondo W, Tintner R, Voung K, Lai D, Ringholz G. Double-blind, placebo-controlled, unforcedtitration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease. Mov Disord. 2005;20:958–963. doi:10.1002/mds.20474
   PubMed Web of Science ®Google Scholar
• Rabey J, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C. Effect of quetiapine in psychoticParkinson’s disease patients: a double-blind labeled study of 3 months’ duration. Mov Disord. 2007;22(3):313–318. doi:10.1002/mds.21116
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Okun MS, Rodriguez RL, et al. Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study. Int J Neurosci. 2009;119:2196–2205. doi:10.3109/00207450903222758
   PubMed Web of Science ®Google Scholar
• Schneider RB, Iourinets J, Richard IH. Parkinson’s disease psychosis: presentation, diagnosis and management. Neurodegener Dis Manag. 2017;7(6):365–376. doi:10.2217/nmt-2017-0028
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Mills R, Revell S, et al. Pimavanserin, a serotonin (2A) receptor inverse agonist, for the treatment of Parkinson’s disease psychosis. Neuropsychopharmacology. 2010;35(4):881–892. doi:10.1038/npp.2009.176
   PubMed Web of Science ®Google Scholar
• Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomized, placebo-controlled Phase 3 trial. Lancet. 2014;383(9916):533–540. doi:10.1016/S0140-6736(13)62106-6
   PubMed Web of Science ®Google Scholar
• Leung IH, Walton CC, Hallock H, Lewis SJ, Valenzuela M, Lampit A. Cognitive training in Parkinson disease: a systematic review and meta-analysis. Neurology. 2015;85(21):1843–1851. doi:10.1212/WNL.0000000000002145
   PubMed Web of Science ®Google Scholar
• da Silva FC, Iop RDR, de Oliveira LC, et al. Effects of physical exercise programs on cognitive function in Parkinson’s disease patients: a systematic review of randomized controlled trials of the last 10 years. PLoS One. 2018;13(2):e0193113. doi:10.1371/journal.pone.0193113
   PubMed Web of Science ®Google Scholar
• Rektorová I, Anderková Ľ. Noninvasive brain stimulation and implications for nonmotor symptoms in Parkinson’s disease. Int Rev Neurobiol. 2017;134:1091–1110.
   PubMed Web of Science ®Google Scholar
• Dinkelbach L, Brambilla M, Manenti R, Brem AK. Non-invasive brain stimulation in Parkinson’s disease: exploiting crossroads of cognition and mood. Neurosci Biobehav Rev. 2017;75:407–418. doi:10.1016/j.neubiorev.2017.01.021
   PubMed Web of Science ®Google Scholar